In an early clinical trial (NCT02208362), IL13Rα2-directed CAR-T cells were delivered into the cerebrospinal fluid, and one remarkable patient experienced tumor regression, even though subsequent recurrence emerged [216, 217]. This evidence concerns the gene IL13RA2 and neoplasm.